POMDOCTOR gets Nasdaq bid-price deficiency notice

POMDOCTOR LIMITED reported that Nasdaq has notified the company its American depositary shares have failed to meet the minimum bid price requirement of US$1.00 for 33 consecutive business days.

Rhea-AI Filing Summary

POMDOCTOR LIMITED reported that Nasdaq has notified the company its American depositary shares have failed to meet the minimum bid price requirement of US$1.00 for 33 consecutive business days. This triggers a compliance period but does not immediately affect listing or trading of the ADSs.

Under Nasdaq rules, Pomdoctor has 180 calendar days, until July 28, 2026, to regain compliance. If the ADS closing bid price is at least US$1.00 for a minimum of ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter. The company states that the notice has no effect on its business operations and that it will take reasonable measures to regain compliance.

Positive

• None.

Negative

• Nasdaq minimum bid price deficiency: The company’s ADSs traded below the US$1.00 minimum bid for 33 consecutive business days, triggering a formal notice and raising the risk of future listing consequences if compliance is not regained within the defined period.

Insights

Equity markets and listing standards analyst

Nasdaq bid-price deficiency raises listing risk but allows time to cure.

POMDOCTOR LIMITED has received a Nasdaq notice because its ADS closing bid price stayed below US$1.00 for 33 consecutive business days. This situation activates Nasdaq’s minimum bid-price rules, which are designed to ensure continued market quality for listed securities.

The company now has a 180-day compliance window, until July 28, 2026, to restore the ADS bid price to at least US$1.00 for ten consecutive business days. If it succeeds, Nasdaq will confirm compliance and the matter ends; if it does not, Nasdaq staff may still grant additional time subject to their determination.

The notice does not currently affect trading of the ADSs or day-to-day operations, according to the company. However, the potential for future listing consequences introduces an overhang that depends on how the share price behaves during the compliance period and any subsequent extension that Nasdaq may permit.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Nasdaq notice did POMDOCTOR LIMITED (POM) receive?

POMDOCTOR LIMITED received a written notice from Nasdaq stating its ADS closing bid price stayed below the US$1.00 minimum for 33 consecutive business days. This constitutes a deficiency under Nasdaq Listing Rule 5450(a)(1) and starts a formal compliance process for the company.

Does the Nasdaq deficiency notice affect trading of POMDOCTOR (POM) ADSs now?

The notice currently has no effect on the listing or trading of POMDOCTOR’s ADSs on Nasdaq. The company states that its business operations remain unchanged while it works within Nasdaq’s compliance framework to address the minimum bid price requirement.

How long does POMDOCTOR LIMITED (POM) have to regain Nasdaq compliance?

POMDOCTOR has a 180-calendar-day compliance period, lasting until July 28, 2026. During this window, it must restore the ADS closing bid price to at least US$1.00 for a minimum of ten consecutive business days to regain compliance with Nasdaq’s bid price rule.

What happens if POMDOCTOR (POM) raises its ADS price back above US$1.00?

If POMDOCTOR’s ADS closing bid price reaches at least US$1.00 for ten consecutive business days within the compliance period, Nasdaq will send written confirmation of compliance. At that point, the minimum bid price matter is considered closed under Nasdaq Listing Rule 5810(c)(3)(A).

What are the potential consequences if POMDOCTOR (POM) does not regain compliance by July 28, 2026?

If POMDOCTOR does not regain compliance by July 28, 2026, Nasdaq staff may determine whether the company is eligible for additional time. The notice indicates this further period is subject to Nasdaq’s determination, so future listing outcomes depend on that separate assessment.

Does the Nasdaq bid price issue change POMDOCTOR LIMITED’s (POM) operations?

The company states that the deficiency letter has no effect on its business operations. POMDOCTOR continues to operate its online medical services platform and indicates it will take reasonable measures to regain compliance with Nasdaq’s minimum bid price requirement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 06:29 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-42749

POMDOCTOR LIMITED

(Exact name of registrant as specified in its charter)

Yongxu Industrial Park
No.19-23 Hejing Road, Dongsha Street
Liwan District, Guangzhou 510000

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒           Form 40-F ☐

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press Release

1 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	POMDOCTOR LIMITED
	By:	/s/ Zhenyang Shi
	Name:	Zhenyang Shi
	Title:	Chairman and Chief Executive Officer

Date: February 2, 2026

2 

Exhibit 99.1 

POMDOCTOR LIMITED Announces Receipt of Nasdaq Notice

GUANGZHOU, China, February 2, 2026 /PRNewswire/ - POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced that it has received a written notification (the “Deficiency Letter”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated January 29, 2026, indicating that for the last 33 consecutive business days, the closing bid price of the Company’s American depositary shares (the “ADSs”) was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Deficiency Letter has no current effect on the listing or trading of the Company’s ADSs on Nasdaq.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until July 28, 2026 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the Compliance Period, the closing bid price of the Company’s ADSs is at least US$1.00 for a minimum of ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event the Company does not regain compliance by July 28, 2026, subject to the determination by the staff of Nasdaq, the Company may be eligible for additional time.

The Deficiency Letter will have no effect on the Company’s business operations, and the Company will take all reasonable measures to regain compliance.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include Internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com